Caribou Biosciences Inc (CRBU) Stock Analysis
Verdict: AVOID
Severe cash burn and recent analyst downgrades overshadow pipeline milestones, creating acute dilution risk within 12 months.
Investment score: 25/100
Analysis as of
Is Caribou Biosciences Inc stock worth reviewing? The TradeMates thesis
The model views CRBU as a high-risk speculative asset defined by severe cash burn, imminent dilution risk, and heavy selling momentum.
7-factor investment score
- Valuation: 25/100 (weight 20%)
- Financial Health: 20/100 (weight 15%)
- Technical Momentum: 10/100 (weight 15%)
- Earnings Quality: 55/100 (weight 15%)
- Insider Sentiment: 20/100 (weight 10%)
- Analyst Consensus: 30/100 (weight 10%)
- Risk-Adjusted Return: 15/100 (weight 15%)
Caribou Biosciences Inc opportunities and risks
What speaks for CRBU
- RMAT Designation and Phase 1 EHA Clinical Data
What speaks against CRBU
- Acute Cash Burn and Impending Equity Dilution
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| CRBU | n/a | 6.1x | n/a | -129.7% | -1030.4% | -156.4% |
| NMAD | n/a | 0.0x | n/a | 0.0% | 0.0% | -10.2% |
| XBIT | n/a | 0.0x | 1.0x | 0.0% | 0.0% | -61.2% |
| SPRO | 8.4x | 1.6x | 2.5x | 100.0% | 17.2% | 28.9% |
| RNTX | n/a | 0.0x | n/a | 0.0% | 0.0% | -85.4% |
| FBIO | 0.6x | 1.0x | n/a | 62.5% | 163.3% | 185.7% |
| Peer median | n/a | 0.0x | n/a | 0.0% | 0.0% | -10.2% |
Frequently asked questions about Caribou Biosciences Inc (CRBU)
Is CRBU stock a good investment?
The TradeMates model rates Caribou Biosciences Inc as AVOID with an investment score of 25/100. The model views CRBU as a high-risk speculative asset defined by severe cash burn, imminent dilution risk, and heavy selling momentum. This is algorithmic model output, not personal investment advice.
Is CRBU stock a buy?
The TradeMates model verdict for CRBU is AVOID with an investment score of 25/100. Treat this as a model signal to review, not a personal buy recommendation.